Quick Answer
Advanced prostate cancer is not one single disease state. It may mean locally advanced cancer that has grown outside the prostate but has not spread to distant organs, or metastatic prostate cancer that has spread to distant lymph nodes, bone or other organs.
Metastatic disease is classified as M1—not “MI.” It can initially remain sensitive to androgen suppression (metastatic hormone-sensitive/castration-sensitive prostate cancer) and later become metastatic castration-resistant prostate cancer (mCRPC).
Modern treatment is far more effective and individualized than older “hormone therapy plus radiation” descriptions suggest. Depending on disease state, treatment can include ADT, androgen-receptor pathway inhibitors, chemotherapy, radiotherapy, PARP-targeted drugs, PSMA-directed radioligand therapy, radium-223 and supportive/palliative care.
There is no reliable fixed life expectancy such as “three years after relapse.” Prognosis varies widely according to stage, metastatic burden, tumor grade/genetics, response to treatment, overall health and access to modern therapy.
What Does “Advanced Prostate Cancer” Mean?
The term is often used in two different ways.
Locally Advanced Prostate Cancer
Locally advanced prostate cancer has grown beyond the prostate into nearby tissue and/or regional pelvic lymph nodes but has not necessarily spread to distant organs.
Examples include:
- T3 disease extending through the prostate capsule;
- seminal-vesicle invasion;
- T4 invasion of nearby structures; and
- regional pelvic lymph-node involvement (N1) without distant metastasis.
Locally advanced disease may still be treated aggressively with curative or long-term disease-control intent.
Metastatic Prostate Cancer
Metastatic disease means cancer has spread to distant sites.
Under the TNM system:
- M1a = non-regional lymph nodes;
- M1b = bone metastases; and
- M1c = other distant organs such as liver or lung.
Read more in our prostate cancer stages guide and metastasis guide.
What Symptoms Can Advanced Prostate Cancer Cause?
Advanced prostate cancer can progress with few or no symptoms, so symptoms are not a reliable way to monitor disease by themselves.
When symptoms occur, they depend on where the cancer is growing or spreading.
| Possible symptom | Possible explanation |
|---|---|
| Worsening urinary obstruction or retention | Local tumor growth, prostate obstruction, treatment effects or a separate urinary condition such as BPH. |
| Blood in urine or semen | Local tumor involvement, but infection, BPH and procedures can cause this too. |
| Persistent bone pain | Possible bone metastases, especially in the spine, pelvis, ribs or long bones. |
| Fracture after minor trauma | Bone weakened by metastases or osteoporosis. |
| Fatigue / weakness | Cancer burden, anemia, treatment effects or other medical problems. |
| Unintentional weight loss | Can occur with advanced cancer but is nonspecific. |
| Leg swelling | Pelvic lymphatic obstruction or a blood clot. |
| Erectile or sexual problems | Cancer, ADT, prior surgery/radiation, vascular disease or other causes. |
For a more detailed symptom discussion, see Advanced Prostate Cancer Symptoms: What They Mean and What to Do.
Spinal-Cord Compression Is an Emergency
- leg weakness;
- numbness or altered sensation;
- difficulty standing or walking;
- new inability to urinate; or
- loss of bladder or bowel control.
These may be signs of metastatic spinal-cord compression. Delay can lead to permanent neurological damage.
How Do Doctors Confirm Whether the Cancer Is Advanced?
The modern assessment uses much more than symptoms and PSA.
Depending on the situation, doctors may review:
- PSA trend;
- Grade Group/Gleason score;
- clinical/pathological TNM stage;
- testosterone level during hormonal therapy;
- CT or MRI;
- bone scan;
- PSMA PET/CT when appropriate;
- complete blood count;
- kidney and liver function;
- alkaline phosphatase;
- tumor genomic testing; and
- germline genetic testing in selected men.
Hormone-Sensitive vs Castration-Resistant Prostate Cancer
This distinction is essential because it determines treatment options.
Metastatic Hormone-Sensitive / Castration-Sensitive Prostate Cancer
The cancer has spread but still responds to reducing or blocking androgen signaling.
This is often abbreviated mHSPC or mCSPC. Recent FDA terminology also uses metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S).
Castration-Resistant Prostate Cancer
The cancer continues to progress despite testosterone being suppressed to a castrate level.
Current EAU guidance defines castration-resistant disease using castrate testosterone plus biochemical, radiological and/or unequivocal clinical progression.
Even after the disease becomes castration-resistant, ADT is usually continued to keep testosterone suppressed.
Treatment of Locally Advanced Prostate Cancer
The old article implied that doctors generally avoid aggressive local treatment once disease is “advanced.” That is no longer accurate.
For medically fit men with locally advanced M0 disease, current EAU guidance generally favors a combination of local treatment plus systemic therapy.
Radiotherapy + Long-Term ADT
For many cN0 locally advanced cancers, external-beam radiotherapy combined with long-term ADT is a standard treatment.
EAU recommends long-term ADT for at least two years in appropriate locally advanced cases.
Adding Abiraterone in Selected Very-High-Risk M0 Disease
For selected cN0M0 patients with at least two major high-risk features—such as cT3–4 disease, Grade Group/Gleason ≥8 and very high PSA—EAU recommends radiotherapy plus long-term ADT and two years of abiraterone.
For clinically node-positive cN1M0 disease, radiotherapy to the prostate/pelvis plus long-term ADT and two years of abiraterone is also an established guideline-supported strategy.
Radical Prostatectomy
Radical prostatectomy may still be considered in selected cN0 locally advanced patients as part of multimodal therapy.
This means surgery is not automatically excluded merely because the tumor extends outside the prostate.
Treatment of Metastatic Hormone-Sensitive Prostate Cancer
This is one of the areas where treatment has changed most dramatically.
For many years, ADT alone was the standard first treatment. Today, ADT alone is generally not enough for a fit patient with newly diagnosed metastatic hormone-sensitive disease who can receive treatment intensification.
ADT + an Androgen-Receptor Pathway Inhibitor
Common systemic partners include:
- abiraterone plus prednisone/prednisolone;
- apalutamide;
- enzalutamide; and
- darolutamide.
These combinations improve survival compared with ADT alone in appropriate patients.
Triplet Therapy
Some medically fit men—particularly those with more extensive disease—may receive:
ADT + docetaxel + an androgen-receptor pathway inhibitor.
Examples of trial-supported triplet strategies include darolutamide or abiraterone added to ADT plus docetaxel.
Radiotherapy to the Prostate in Selected Metastatic Disease
In selected men with newly diagnosed low-volume metastatic disease, radiotherapy to the prostate itself can improve outcomes when added to systemic treatment.
This is another reason the old statement that local treatment should generally be avoided in advanced disease is outdated.
New 2026 Option: Pluvicto Earlier in Metastatic Disease
Lutetium-177 vipivotide tetraxetan (Pluvicto) is a PSMA-targeted radioligand therapy.
On July 31, 2026, the U.S. FDA approved Pluvicto in combination with an androgen-receptor pathway inhibitor for adults with PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
Patients must be selected using an approved PSMA PET imaging agent based on PSMA expression.
This major 2026 change shows why advanced prostate-cancer treatment should no longer be described simply as “hormones, radiation or chemotherapy.”
Treatment of Metastatic Castration-Resistant Prostate Cancer
When metastatic cancer progresses despite castrate testosterone, treatment selection depends heavily on what the patient has already received.
Current options can include:
Androgen-Receptor Pathway Therapy
Depending on prior exposure, agents such as abiraterone or enzalutamide may be considered.
Chemotherapy
Docetaxel remains an important treatment. Cabazitaxel is an established option after docetaxel in appropriate patients.
PARP-Targeted Therapy
Men with selected DNA-repair alterations—particularly BRCA1/2 and other homologous-recombination repair abnormalities—may be eligible for PARP inhibitors or PARP-containing combinations.
Examples include:
- olaparib;
- rucaparib;
- niraparib-containing treatment; and
- talazoparib-containing treatment.
PSMA Radioligand Therapy
Pluvicto also has an established role in PSMA-positive metastatic castration-resistant prostate cancer, with eligibility depending on prior treatment and the current regulatory indication.
Radium-223
Radium-223 can be considered for selected men with symptomatic bone-predominant mCRPC and no unsuitable visceral disease pattern.
Sipuleucel-T
This cellular immunotherapy can be considered in selected minimally symptomatic metastatic castration-resistant disease.
Why Genetic and Molecular Testing Matters
Advanced prostate cancer is increasingly treated according to molecular characteristics rather than stage alone.
Testing may identify:
- BRCA1/BRCA2 mutations;
- other homologous-recombination repair alterations;
- mismatch-repair deficiency or microsatellite instability; and
- other actionable tumor features.
Some findings can guide targeted treatment. A hereditary mutation may also have implications for close relatives.
What About Bone Metastases?
Bone is a common site of prostate-cancer spread.
Treatment may include:
- effective systemic prostate-cancer treatment;
- pain medication;
- focused external-beam radiotherapy;
- radium-223 in selected disease;
- zoledronic acid or denosumab in appropriate settings; and
- surgery or orthopedic stabilization when a bone is at high risk of fracture.
Bone-protective medicines require monitoring for low calcium and, rarely, osteonecrosis of the jaw.
ADT Itself Can Weaken Bone
Androgen-deprivation therapy can reduce bone mineral density even when the cancer has not spread to bone.
Current EAU guidance recommends:
- baseline bone-mineral-density assessment for men starting long-term ADT;
- adequate calcium and vitamin D intake;
- exercise;
- fracture-risk assessment; and
- anti-resorptive treatment when indicated.
How Is Advanced Prostate Cancer Followed?
Follow-up must be individualized.
EAU recommends that men with metastatic M1 disease are generally reviewed at least every 3–6 months, including imaging at regular intervals.
Monitoring commonly includes:
- symptoms and functional status;
- PSA;
- testosterone during ADT;
- hemoglobin;
- kidney function;
- liver tests;
- alkaline phosphatase;
- lipids and HbA1c during long-term ADT; and
- imaging according to disease state and treatment.
Advanced Prostate Cancer Prognosis
There is no single prognosis that applies to every man with “advanced prostate cancer.”
Important factors include:
- whether disease is locally advanced or distantly metastatic;
- hormone-sensitive versus castration-resistant status;
- number and location of metastases;
- Grade Group and tumor biology;
- presence of visceral metastases;
- PSA and alkaline-phosphatase trends;
- genomic alterations;
- performance status and other illnesses;
- response and duration of response to treatment; and
- availability of subsequent effective therapies.
What Do Population Survival Statistics Show?
The American Cancer Society reports current U.S. SEER-based 5-year relative survival estimates for men diagnosed from 2015–2021:
| SEER category | 5-year relative survival |
|---|---|
| Localized | >99% |
| Regional | >99% |
| Distant metastatic | About 38% |
Is There a Three-Year “Relapse” Rule?
No.
The old article’s statement that relapse occurs after approximately three years is not a medically reliable rule.
Some metastatic hormone-sensitive cancers remain controlled for years; others progress sooner. Some men develop castration-resistant disease relatively quickly, while others have prolonged responses to intensified hormonal treatment.
Similarly, becoming castration-resistant does not mean that treatment options have been exhausted. Several therapies can extend survival and control symptoms after progression.
Can Advanced Prostate Cancer Be Cured?
The answer depends on what “advanced” means.
Locally Advanced / Regional M0 Disease
Some patients can still be treated aggressively with curative or long-term control intent using radiotherapy, ADT, systemic intensification and/or selected surgery.
Distant Metastatic M1 Disease
Widespread metastatic prostate cancer is generally considered treatable rather than routinely curable.
Modern treatment aims to:
- extend survival;
- delay progression;
- prevent fractures and neurological complications;
- control pain and urinary symptoms; and
- maintain quality of life.
Does “Wait and Watch” Make Sense Just Because the Patient Is Old?
No.
The old article implied that most advanced patients are elderly and may have less than ten years of normal life expectancy, making watchful waiting the “best” option.
That is too simplistic.
Age alone should not determine whether a patient receives modern systemic treatment.
Treatment intensity depends on:
- frailty and functional status;
- comorbidities;
- life expectancy;
- cancer burden and symptoms;
- treatment goals; and
- patient preferences.
A fit man in his 80s may benefit from active treatment. A younger but severely frail patient may need a less intensive plan.
Supportive and Palliative Care Should Start Early When Needed
Supportive or palliative care does not mean cancer treatment has stopped.
It can be used alongside ADT, chemotherapy, radioligand therapy and other cancer-directed treatments.
Supportive care can address:
- pain;
- fatigue;
- hot flashes;
- bone health;
- urinary problems;
- sexual dysfunction;
- anxiety and depression;
- sleep problems;
- nutrition;
- constipation and nausea; and
- caregiver burden.
Nutrition and Exercise During Advanced Treatment
There is no single “advanced prostate cancer diet.”
Men losing weight or muscle may need more protein and calories. Men on long-term ADT may instead gain fat, lose muscle and develop insulin resistance.
Current EAU guidance supports:
- maintaining a healthy weight;
- regular supervised aerobic and resistance exercise when safe;
- stopping smoking;
- limiting excessive alcohol;
- monitoring diabetes and cholesterol; and
- protecting bone health.
Questions to Ask the Oncology Team
- Is my disease locally advanced, regional-node positive or distantly metastatic?
- If metastatic, is it M1a, M1b or M1c?
- Is it still hormone-sensitive or is it castration-resistant?
- What is my current PSA trend and testosterone level?
- Do I need PSMA PET/CT or other updated imaging?
- Should I receive ADT plus an ARPI rather than ADT alone?
- Am I a candidate for triplet therapy?
- Would radiotherapy to the prostate help in my disease state?
- Do I need germline and tumor genomic testing?
- Could a PARP inhibitor or PSMA radioligand therapy be appropriate?
- Do I need bone-density testing or bone-protective treatment?
- What symptoms require urgent contact?
The phrase “advanced prostate cancer” should never be the end of the explanation. I would want every patient to know whether the cancer is locally advanced or metastatic, whether it is still hormone-sensitive, where it has spread, and what treatments have already been used.
A modern treatment plan cannot be reduced to “radiation, chemotherapy or hormones.” Combination hormonal therapy, targeted drugs, genomic testing, PSMA-directed treatment and carefully selected local treatment have changed the outlook substantially.
I would also avoid giving an individual patient a fixed survival estimate from a website. Population statistics are useful for context, but the most meaningful prognosis comes from the oncologist who knows the disease burden, pathology, treatment response and overall health.
Dr. Albana Greca, MD, MMedSc
Family Physician / General Practitioner
Founder & Lead Medical Author, Prostate Treatment Options
Medical References
European Association of Urology. 2026 Guidelines on Prostate Cancer: locally advanced disease, first-line treatment of hormone-sensitive metastatic disease, castration-resistant prostate cancer, follow-up and quality of life.
National Cancer Institute. Prostate Cancer Treatment (PDQ); Hormone Therapy for Prostate Cancer.
U.S. Food and Drug Administration. July 31, 2026 approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) with androgen-receptor pathway inhibitor therapy for PSMA-positive metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.
American Cancer Society. Prostate Cancer Survival Rates, updated January 2026.
Last evidence update: September 2026.
Medical information notice: This article is for general education and does not replace individualized oncology care. Treatment for advanced prostate cancer depends on stage, prior therapy, tumor biology, symptoms and overall health.